Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas
1. Response to treatment was noted in 33% of the high-grade glioma cohort and 69% of the low-grade cohort. 2. ...
1. Response to treatment was noted in 33% of the high-grade glioma cohort and 69% of the low-grade cohort. 2. ...
Click to read the study in the European Journal of Cancer.
Click to read the study in the European Journal of Cancer.
Click to read the study in the European Journal of Cancer.
Click to read the study in Nature Communications
Click to read the study in Clinical Cancer Research
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.